Novo Nordisk A/S, NVO is in the exchange NYSE and its industry is Drug Manufacturers – Other in the sector of Healthcare. Based in Denmark, Novo Nordisk A/S, NVO has a market cap of 95735.57. Since its IPO date on the 1/4/1982, Novo Nordisk A/S, NVO performance year to date is -15.99%. Today Novo Nordisk A/S, NVO has gained -0.21%, with a current price of 47.39.
Ownership of the company is 26.40% for insider ownership while institutional ownership is 10.00%. The management of the company have seen the company have a payout ratio of 45.20%. Return of assets are at 41.50%, with return on investment at 85.00%.
In terms of debt levels and profit levels, Novo Nordisk A/S, NVO is seeing a long-term debt/equity of 0. While Total debt/equity is 0.01. With a profit margin of 32.70%, this is combined with a gross margin of 84.80%, and operating margin of 43.40%. Novo Nordisk A/S ability to meet debt levels, with a current ratio of 1.3, while the quick ratio is 0.9.
For the last year Novo Nordisk A/S, NVO has seen a EPS growth of 34.30%. A performance for the year of -11.24%. The 52-week high is -17.48%, and the 52-week low is 5.46%. The average volume for Novo Nordisk A/S, NVO is 3024947.
With a target price of 57, can Novo Nordisk A/S, NVO reach this target? Looking at the value indicators of Novo Nordisk A/S, NVO. Novo Nordisk A/S has a P/E of 22.03 and a forward P/E of 19.59. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.08. Novo Nordisk A/S also has a P/S and a P/B of 5.69 and 18.55 respectively. For P/cash, Novo Nordisk A/S has a value of 41.23, while it is 30.48 for P/free cash flow.
At the current price of 47.39, Novo Nordisk A/S has a dividend yield of 2.97%. We see a return on equity of 84.90%.
Looking more long-term Novo Nordisk A/S, is projected to get an EPS growth for the next five years of 10.60%. In the short-term an EPS growth of 6.78% in the next year is forecasted. This is after a EPS growth of 34.30% for this year and for the last five years a 22.40% growth has been seen.